Numinus Wellness (NUMI) Q4 2024 earnings summary

Executive summary

• Revenue for Q4 2024 reached $1.2 million, up 16.4% over Q3 2024.

• Gross profit was $0.3 million, reversing a loss of $0.05 million in Q3 2024.

• Significant leadership changes included a new CEO and CFO appointed after quarter end.

• Sale of the U.S. wellness clinic network for US$3.53 million, with operations now classified as discontinued.

• Psychedelic-Assisted Therapy Training Program approved in Colorado, expanding regulatory reach.

Financial highlights

• Consolidated revenues increased by 10.4% quarter over quarter.

• Gross margin improved to 25.3% in Q4 2024 from a loss of 4.6% in Q3 2024.

• Operating expenditures dropped to $931,198 from $2.9 million in the previous quarter due to cost containment.

• Cash position at quarter end was $2.0 million, with working capital of $1.2 million.

Outlook and guidance

• Forward-looking statements highlight risks related to profitability, regulatory approvals, and market competition.

• Emphasis on expanding training and clinical research partnerships to drive future growth.